Table 1 Baseline characteristics of patients supported with the Impella 5.0 device
From: Management and outcome of patients supported with Impella 5.0 for refractory cardiogenic shock
Patients characteristics | Total (n = 40) |
|---|---|
Gender (female/male) | 5/35 |
Age, years | 57 [48–63] |
Surgical access femoral/axillary | 30/10 |
Etiology of cardiogenic shock | Â |
 Acute ST-elevation myocardial infarction | 17 (43) |
 Dilated cardiomyopathy | 12 (30) |
 Postcardiotomy | 7 (18) |
 Others | 4 (10) |
Context of MCS | Â |
 Cardiac arrest before MCS | 9 (23) |
 Transfer from others centers with MCS | 4 (10) |
Severity at ICU admission | Â |
 SOFA score | 11 [9–14] |
 SAPS II score | 58 [46–76] |
Severity and treatment at t0MCS | Â |
 Mean arterial pressure, mmHg | 60 [50–68] |
 SOFA score | 12 [10–14] |
 Blood lactate, mmol/l | 3.8 [1.7–5.9] |
 IAPB support | 11 (28) |
 Inotrope support | 32 (80) |
 Mechanical ventilation | 29 (73) |
MCS description | Â |
 Impella 5.0 alone | 25 (62.5 %) |
 Impella 5.0 added to ongoing ECMO | 15 (37.5 %) |
 Duration of Impella support, days | 7 [5–10] |
 Duration of ECMO, days | 5 [3–8] |
 Total duration of MCS, days | 7 [5–10] |